Commentary Paper: Dr. Manuel Montero-Odasso
The development of parenteral anti-amyloid therapies (AATs) for Alzheimer’s disease (AD) marks a new era in cognitive therapeutics.(1) Currently or predicted soon-to-be available AATs (e.g., lecanemab, donanemab) appear modestly effective for patients with amyloid positive Mild Cognitive Impairment (MCI) or early-stage AD dementia.
